BetaNone of it through sales. No officer or director reported an open-market sale in this period.
No officer or director sold shares in this period. 10 are left out Disclosed company stock is not an insider's whole wealth.i
Left out: Travis Murdoch, Jason Coloma, David Malek, Christopher Viehbacher, James Rickey, Michele Anderson, Tim Lohoff, Erez Chimovits, David Lubner and Jasper Bos (share of stake is being verified).
No officer or director trades were reported for the past 30 days. The most recent before that:
| Who | Shares | Price | % of total stake | Total stake after | Trade date | Filed |
|---|---|---|---|---|---|---|
| Travis Murdoch CEO and President, Director | 83,333 | $18.00 | n/a | n/a | Aug 7, 2026 | Aug 7, 2026 |
| Christopher Viehbacher Director | 83,333 | $18.00 | n/a | n/a | Aug 7, 2026 | Aug 7, 2026 |
| David Lubner Director | 55,555 | $18.00 | n/a | n/a | Aug 7, 2026 | Aug 7, 2026 |
| James Rickey Chief Financial Officer | 27,777 | $18.00 | n/a | n/a | Aug 7, 2026 | Aug 7, 2026 |
| David Malek Director | 4,166 | $18.00 | n/a | n/a | Aug 7, 2026 | Aug 7, 2026 |
| Michele Anderson Chief Development Officer | 1,111 | $18.00 | n/a | n/a | Aug 7, 2026 | Aug 7, 2026 |
ORBIMED ADVISORS LLC, Forbion Growth Opportunities Fund III Cooperatief U.A. and AH Bio Fund IV, L.P. and 3 more reported no open-market sales in the past 12 months. Large shareholders and the funds or companies that board members represent are not part of management, so they are left out of the figures above.
No. Travis Murdoch reported no open-market sales in the past 12 months.
Yes. 6 officers or directors reported 6 purchases in the past 12 months (Form 4 code P; rows the filings describe as reinvested dividends, plan purchases, private deals or moves into the person's own trust are not counted).
| Who sold | Amount | % of holdings | Trading plan |
|---|
Board members representing outside shareholders, reported separately: Vineeta Agarwala, Erez Chimovits. Details
Outside holder, reported separately: ORBIMED ADVISORS LLC (a 10% owner, not part of management). No open-market sales reported in the period. Latest filing
Outside holder, reported separately: Forbion Growth Opportunities Fund III Cooperatief U.A. (a 10% owner, not part of management). No open-market sales reported in the period. Latest filing
Outside holder, reported separately: AH Bio Fund IV, L.P. (a 10% owner, not part of management). No open-market sales reported in the period. Latest filing
Outside holder, reported separately: Jiangsu Hengrui Pharmaceuticals Co., Ltd. (a 10% owner, not part of management). No open-market sales reported in the period. Latest filing
Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.
| Insider | Held Oct 13, 2025 | Sold | Held Oct 13, 2026 | Still held | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Travis Murdoch!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Travis Murdoch are complete. CEO and President, Director | n/a | 0 | n/a | n/a | ||||||||||||
Vesting, gifts, unvested awards and holding lines for Travis MurdochHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Travis Murdoch are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) Stock options (not counted as shares):
Estimate: options held × ($18.00 − strike price), using the most recent insider trade price on Form 4 (Aug 7, 2026), not a market close. | ||||||||||||||||
Jason Coloma!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Jason Coloma are complete. Director | n/a | 0 | n/a | n/a | ||||||||||||
Vesting, gifts, unvested awards and holding lines for Jason ColomaHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jason Coloma are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) | ||||||||||||||||
David Malek!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for David Malek are complete. Director | n/a | 0 | n/a | n/a | ||||||||||||
Vesting, gifts, unvested awards and holding lines for David MalekHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for David Malek are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) Stock options (not counted as shares):
Estimate: options held × ($18.00 − strike price), using the most recent insider trade price on Form 4 (Aug 7, 2026), not a market close. | ||||||||||||||||
Christopher Viehbacher!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Christopher Viehbacher are complete. Director | n/a | 0 | n/a | n/a | ||||||||||||
Vesting, gifts, unvested awards and holding lines for Christopher ViehbacherHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Christopher Viehbacher are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) Stock options (not counted as shares):
Estimate: options held × ($18.00 − strike price), using the most recent insider trade price on Form 4 (Aug 7, 2026), not a market close. | ||||||||||||||||
James Rickey!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for James Rickey are complete. Chief Financial Officer | n/a | 0 | n/a | n/a | ||||||||||||
Vesting, gifts, unvested awards and holding lines for James RickeyHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for James Rickey are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) Stock options (not counted as shares):
Estimate: options held × ($18.00 − strike price), using the most recent insider trade price on Form 4 (Aug 7, 2026), not a market close. | ||||||||||||||||
Michele Anderson!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Michele Anderson are complete. Chief Development Officer | n/a | 0 | n/a | n/a | ||||||||||||
Vesting, gifts, unvested awards and holding lines for Michele AndersonHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Michele Anderson are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) Stock options (not counted as shares):
Estimate: options held × ($18.00 − strike price), using the most recent insider trade price on Form 4 (Aug 7, 2026), not a market close. | ||||||||||||||||
Tim Lohoff!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Tim Lohoff are complete. Director | n/a | 0 | n/a | n/a | ||||||||||||
Vesting, gifts, unvested awards and holding lines for Tim LohoffHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Tim Lohoff are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) Stock options (not counted as shares):
Estimate: options held × ($18.00 − strike price), using the most recent insider trade price on Form 4 (Aug 7, 2026), not a market close. | ||||||||||||||||
Erez Chimovits!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Erez Chimovits are complete. Director | n/a | 0 | n/a | n/a | ||||||||||||
Vesting, gifts, unvested awards and holding lines for Erez ChimovitsHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Erez Chimovits are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) Stock options (not counted as shares):
Estimate: options held × ($18.00 − strike price), using the most recent insider trade price on Form 4 (Aug 7, 2026), not a market close. | ||||||||||||||||
David Lubner!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for David Lubner are complete. Director | n/a | 0 | n/a | n/a | ||||||||||||
Vesting, gifts, unvested awards and holding lines for David LubnerHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for David Lubner are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) Stock options (not counted as shares):
Estimate: options held × ($18.00 − strike price), using the most recent insider trade price on Form 4 (Aug 7, 2026), not a market close. | ||||||||||||||||
Jasper Bos!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Jasper Bos are complete. Director | n/a | 0 | n/a | n/a | ||||||||||||
Vesting, gifts, unvested awards and holding lines for Jasper BosHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Jasper Bos are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) Stock options (not counted as shares):
Estimate: options held × ($18.00 − strike price), using the most recent insider trade price on Form 4 (Aug 7, 2026), not a market close. | ||||||||||||||||
Holdings and share of stake for Braveheart Bio, Inc. are being verified, so no balances, unit counts or percentages are shown. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings.
Directors whose reported holdings sit mostly in an investment fund or a corporate shareholder they represent, not in their own name, with beneficial ownership disclaimed except for their own financial interest. Listed and sourced here; not part of the management totals or the answer line. Shares a fund hands to its own investors are distributions, not sales.
| Board member | Held Oct 13, 2025 | Sold | Held Oct 13, 2026 | Still held |
|---|---|---|---|---|
Vineeta Agarwala!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Vineeta Agarwala are complete. Director | n/a | 0 | n/a | n/a |
Vesting, gifts, unvested awards and holding lines for Vineeta AgarwalaHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Vineeta Agarwala are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) | ||||
Erez Chimovits!Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Erez Chimovits are complete. Director | n/a | 0 | n/a | n/a |
Vesting, gifts, unvested awards and holding lines for Erez ChimovitsHoldings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Erez Chimovits are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts) | ||||
Holdings and share of stake are being verified. Balances, unit counts and every share-of-stake figure for Braveheart Bio, Inc. are held back until that check is finished. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings and are complete.
External context: we only cite outside events when a documented connection exists. None is shown for this period.
All 29 Forms 3, 4 and 5 on record for Braveheart Bio, Inc. (SEC CIK 2131524), filed from Aug 5, 2026 to Aug 14, 2026; 29 of them were filed in the 12 months this page covers, retrieved from SEC EDGAR on Oct 13, 2026. Prices are the ones reported in each filing, often weighted averages.
Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.
Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".
Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.